<< Read Full Article
<< Read Full Article
Rival Psoriasis Drugs Both Come Off Well in a Face-Off
Genentech(DNA Quote) and Biogen(BGEN Quote) came out strongly Thursday in the great psoriasis drug showdown. Each improved its standing, but neither emerged as an obvious choice.
Speaking at the International Psoriasis Symposium in San Francisco, Genentech and partner Xoma (XOMA Quote) released late-stage test results that showed its drug, Xanelim, was effective in reducing the painful, itchy skin lesions that makes psoriasis such a debilitating disease.
Biogen countered with results for its drug, Amevive, which quelled concerns about potentially dangerous side effects.
Questions Remain for Each
...Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,340.98 | 1,099.31 | 2,185.83 | 34.82 |
Oil *
73.25
|
|
DOWN
100.14
|
DOWN
9.87
|
DOWN
21.08
|
DOWN
1.14
|
10 Yr
3.48%
SPDR Gold
108.10
|
|
-0.96%
|
-0.89%
|
-0.96%
|
-3.17%
|
Data delayed 20 minutes |
Connect with TheStreet